Silicone oil-induced ocular hypertension and glaucomatous neurodegeneration in mouse

Jie Zhang1,2†, Liang Li†, Haoliang Huang1, Fang Fang1,3, Hannah C Webber1, Pei Zhuang1, Liang Liu1, Roopa Dalal1, Peter H Tang1,4, Vinit B Mahajan1,4, Yang Sun1,4, Shaohua Li2, Mingchang Zhang2, Jeffrey L Goldberg1, Yang Hu1*

1Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, United States; 2Department of Ophthalmology, Tongji Medical College, Union Hospital, Huazhong University of Science & Technology, Wuhan, China; 3Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, China; 4Department of Ophthalmology, Veterans Affairs Palo Alto Health Care, Palo Alto, United States

Abstract Understanding the molecular mechanism of glaucoma and development of neuroprotectants is significantly hindered by the lack of a reliable animal model that accurately recapitulates human glaucoma. Here, we sought to develop a mouse model for the secondary glaucoma that is often observed in humans after silicone oil (SO) blocks the pupil or migrates into the anterior chamber following vitreoretinal surgery. We observed significant intraocular pressure (IOP) elevation after intracameral injection of SO, and that SO removal allows IOP to return quickly to normal. This simple, inducible and reversible mouse ocular hypertension model shows dynamic changes of visual function that correlate with progressive retinal ganglion cell (RGC) loss and axon degeneration. It may be applicable with only minor modifications to a range of animal species in which it will generate stable, robust IOP elevation and significant neurodegeneration that will facilitate selection of neuroprotectants and investigating the pathogenesis of ocular hypertension-induced glaucoma.

DOI: https://doi.org/10.7554/eLife.45881.001

Introduction

Glaucoma is the most common cause of irreversible blindness and will affect more than 100 million individuals between 40 and 80 years of age by 2040 (Tham et al., 2014). Annual direct medical costs to treat this disease in 2 million patients in the United States totaled $2.9 billion (Varma et al., 2011). Glaucoma is a neurodegenerative disease characterized by injury to the axons of retinal ganglion cells (RGCs) followed by progressive degeneration of RGC somata and axons within the retina and Wallerian degeneration of the myelinated axons in the optic nerve (ON) (Quigley, 1993; Quigley et al., 1995; Libby et al., 2005; Howell et al., 2007; Weinreb and Khaw, 2004; Calkins, 2012; Burgoyne, 2011; Nickells et al., 2012; Jonas et al., 2017). The level of intraocular pressure (IOP) is the most common risk factor (Singh and Shrivastava, 2009). Current clinical therapies target reduction of IOP to retard glaucomatous neurodegeneration (The AGIS Investigators, 2000; Early Manifest Glaucoma Trial Group et al., 2002; Lichter et al., 2001), but neuroprotectants are critically needed to prevent degeneration of RGCs and ON. Similar to other chronic neurodegenerative diseases (Varma et al., 2008), the search for neuroprotectants to treat glaucoma continues. To longitudinally assess the molecular mechanisms of glaucomatous degeneration and the efficacy of
neuroprotectants, a reliable, reproducible, and inducible experimental ocular hypertension/glaucoma model is essential.

The rodent serves as the mammalian experimental species of choice for modeling human diseases and large-scale genetic manipulations. Various rodent ocular hypertension models have been developed including spontaneous mutant or transgenic mice and rats and mice with inducible blockage of aqueous humor outflow from the trabecular meshwork (TM) (Pang and Clark, 2007; Morrison et al., 2008; McKinnon et al., 2009; Chen and Zhang, 2015). While genetic mouse models are valuable to understand the roles of a specific gene in IOP elevation and/or glaucomatous neurodegeneration, the pathologic effects may take months to years to manifest. Inducible ocular hypertension that develops more quickly and is more severe term would be preferable for experimental manipulation and general mechanism studies, especially for neuroprotectant screening. Injection of hypertonic saline and laser photocoagulation of the episcleral veins and TM are commonly used in rats and larger animals (Morrison et al., 2008). Although similar techniques also produce ocular hypertension in mice (Aiha et al., 2003; Grozdanic et al., 2003; Yun et al., 2014), they are technically challenging, and irreversible ocular tissue damage and intraocular inflammation complicate their interpretation (Pang and Clark, 2007; Chen and Zhang, 2015). Intracameral injection of microbeads to occlude aqueous humor circulation through TM produces excellent IOP elevation and glaucomatous neurodegeneration (Sappington et al., 2010; Chen et al., 2011; Cone et al., 2010; Samsel et al., 2011). However, retaining microbeads at the angle of the anterior chamber and controlling the degree of aqueous outflow blockade are difficult. Furthermore, its lengthy duration (6–12 weeks after microbeads injection) causes death of only less than 30% of RGC (Cone et al., 2010; Ito et al., 2016; Yang et al., 2016), leaving a narrow window for preclinical testing of neuroprotective therapies. It is therefore critically important to develop a simple but effective ocular hypertension model in mice that closely resembles human glaucoma, and that can be readily adapted to larger animals with minimal confounding factors.

Secondary glaucoma with acutely elevated IOP occurs as a post-operative complication following the intravitreal use of silicone oil (SO) in human vitreoretinal surgery (Ichhpujani et al., 2009; Kornmann and Gedde, 2016). SO is used as a tamponade in retinal detachment repair because of its buoyancy and high surface tension. However, SO is lighter than the aqueous and vitreous fluids and an excess can physically occlude the pupil, which prevents aqueous flow into the anterior chamber. This obstruction increases aqueous pressure in the posterior chamber and displace the iris anteriorly, which causes angle-closure, blockage of aqueous outflow through TM, and a further increase in IOP. Prophylactic peripheral iridotomy that maintains the circulation between anterior and posterior chambers normally prevents this type of secondary glaucoma. Based on this clinical experience, we developed a simple procedure for intracameral injection of SO to block the pupil, which causes acute ocular hypertension and significant RGC and ON degeneration. The present study demonstrates that this model, which may be adaptable to larger species, induces stable IOP elevation and profound neuronal response to ocular hypertension in the retina that will expedite selection of neuroprotectants and establishing the pathogenesis of acute ocular hypertension-induced glaucoma.

### Results

**Intracameral SO injection induces ocular hypertension by blocking the pupil and aqueous humor drainage**

Although intravitreal injection of SO in vitreoretinal surgeries can cause post-operative secondary glaucoma in humans (Ichhpujani et al., 2009; Kornmann and Gedde, 2016), we reasoned that direct injection of SO into the anterior chamber of mice would be more efficient, preventing the need to remove the vitreous and reducing toxicity due to direct contact with the retina. As illustrated in Figure 1A,B and Video 1, after intracameral injection SO forms a droplet in the anterior chamber that contacts the surface of the iris and tightly seals the pupil due to high surface tension.

To test whether SO blocks migration of liquid from the back of the eye to the anterior chamber, we injected dye (DiI) into the posterior chamber and visualized its migration into the anterior chamber. In dramatic contrast to a normal naïve eye, in which copious dye passed through the pupil and appeared in the anterior chamber almost immediately after injection, no injected dye reached the
Figure 1. Silicone oil-induced ocular hypertension under-detected (SOHU) mouse model. (A) Cartoon illustration of SO intracameral injection, pupillary block, closure of the anterior chamber angle, and reopening of the angle of anterior chamber after pupil dilation. (B) Representative anterior chamber OCT images of SOHU eyes in living animals showing the relative size of SO droplet (blue arrow) to pupil (black arrow) and the corresponding closure or opening of the anterior chamber angle before and after pupil dilation. Red curved arrow indicates the direction of aqueous humor flow. (C) Figure 1 continued on next page

Zhang et al. eLife 2019;8:e45881. DOI: https://doi.org/10.7554/eLife.45881
anterior chamber of the SO eye (Videos 2 and 3). This result indicates that SO causes effective pupillary block.

The ciliary body constantly produces aqueous humor, which accumulates in the posterior chamber and pushes the iris forward. When the iris root touches the posterior corneal surface, the anterior chamber angle closes (Figure 1A), as evidenced by live anterior chamber optical coherence tomography (OCT) (Figure 1B). The angle closure can further impede the outflow of aqueous humor through TM and may also contribute to IOP elevation. Dilation of the pupil until it is larger than the SO droplet can relieve the pupillary block. Video 4 shows that after pupil dilation aqueous humor floods into the anterior chamber and pushes the SO droplet away from the iris, which reopens the anterior chamber angle (Figure 1A,B). Together, these results characterize the series of reactions initiated by intracameral SO injection, including the physical mechanisms of SO-induced pupillary block, posterior accumulation of aqueous humor, peripheral angle-closure, and IOP elevation.

We measured the IOP of the experimental eyes once weekly for 8 weeks after a single SO injection and the contralateral control (CL) eyes after a single normal saline injection. Surprisingly, IOP was lower in the SO eyes than in CL eyes when measured immediately after anesthetizing the animals with isoflurane (Figure 1C). The TonoLab tonometer used to measure mouse IOP is based on a rebound measuring principle that uses a very light weight probe to make momentary contact with the center of the cornea, which primarily measures the pressure of anterior chamber. Measurements over extended periods of time showed the IOP of the SO eyes to be progressively and significantly elevated, in dramatic contrast to the CL eyes, in which IOP decreased over time. The increasing IOP in the SO eyes closely correlated with the change in pupillary size, indicating a significant role of pupillary block. Pupillary dilation removed the pupillary block and allowed the tonometer to detect higher IOP after aqueous humor migration into the anterior chamber, which reflects the elevated IOP in the posterior segment of the eye. Pupillary size reached its maximum and IOP reached to its plateau about 12–15 min after induction of anesthesia with continuous isoflurane inhalation. In mice in which we measured IOP for as long as 30 min under anesthesia, however, the IOP eventually declined, indicating effective TM clearance of aqueous during this time (Figure 1—figure supplement 1). Therefore, we standardized the time period (12–15 min after induction of anesthesia) for measuring IOP in later experiments. Because the unique feature of this novel experimental glaucoma model is that the ocular hypertension is under-detected in non-dilated eyes, we named it ‘SO-induced ocular hypertension under-detected (SOHU)”.

IOP elevation in the SO eye started as early as 2 days post injection (2dpi) and remained stable for at least 8 weeks (the longest time point we tested) at an IOP about 2.5 fold that of CL eyes, if the diameter of the SO droplet was larger than 1.5 mm (Figure 1D). We achieved this size of SO droplet in about 80% of mice, but in the 20% of mice with a small SO droplet (<1.5 mm) in the anterior chamber due to poor injection or oil leaking, in which the IOP initially increased but dropped soon afterwards.
Therefore, by observing the size of the SO droplet, it is convenient for us to identify mice very early that will not show elevated IOP and exclude them from subsequent experiments.

**Visual function deficits and dynamic morphological changes in SOHU eyes of living animals**

To determine the dynamic changes in RGC morphology and function in SOHU eyes, we longitudinally measured the thickness of the ganglion cell complex (GCC) by OCT (Nakano et al., 2011), visual acuity by the optokinetic tracking response (OKR) (Prusky et al., 2004; Douglas et al., 2005), and general RGC function by pattern electroretinogram (PERG) (Porciatti, 2015) in living animals. Clinically, the thickness of the retinal nerve fiber layer (RNFL) measured by posterior OCT serves as a reliable biomarker for glaucomatous RGC degeneration (Balcer et al., 2015; Aktas et al., 2016; Costello et al., 2006). Because the mouse RNFL is too thin to be reliably measured, we used the thickness of GCC (Nakano et al., 2011), including RNFL, ganglion cell layer (GCL) and inner plexiform layer (IPL) together, to monitor degeneration of RGC axons, somata, and dendrites caused by ocular hypertension. GCC in SOHU eyes became gradually and progressively thinner (about 84%, 65%, 61% and 53% of CL eyes) at 1, 3, 5, and 8 weeks post injection (wpi). GCC thinning is statistically significant at 5 and 8 wpi compared to 1 wpi (Figure 2A,B). These results indicate progressive RGC degeneration in response to IOP elevation in SOHU eyes.

OKR is a natural reflex that objectively assesses mouse visual acuity (Prusky et al., 2004; Douglas et al., 2005). The mouse eye will only track a grating stimulus that is moving from the temporal to nasal visual field, which allows both eyes to be measured independently (Douglas et al., 2005; Douglas et al., 2006). It has been used to establish correlations between visual deficit and RGC loss in the DBA/2 glaucoma mouse model (Burroughs et al., 2011). The visual acuity of SOHU eyes decreased rapidly at 1wpi, which may due to the presence of SO in the anterior chamber. However, the further decreased visual acuity at 5 and 8 wpi compared to 1 wpi indicates progressive visual function deficits in the SOHU eyes (Figure 2C). PERG is an important electrophysiological assessment of general RGC function, in which the ERG responses are stimulated with contrast-reversing horizontal bars alternating at constant mean luminance (Porciatti, 2015). Our PERG system measured both eyes at the same time, so there was an internal control to use as a reference and normalization to minimize the variations. Consistent with visual acuity deficit, the P1-N2

---

**Video 2.** Dye migration from vitreous chamber to anterior chamber in naive eyes. Dil injected into the posterior chamber of the naive eye and migrated into the anterior chamber. DOI: https://doi.org/10.7554/eLife.45881.005

**Video 3.** Dye migration blocked in SOHU eyes. Dil injected into the posterior chamber of the SOHU eye and there was no Dil detected in the anterior chamber. DOI: https://doi.org/10.7554/eLife.45881.006

**Video 4.** SO droplet flows away from pupil after dilation. After pupil dilation, the SO droplet was pushed away from the pupil and iris by aqueous humor flooded into the anterior chamber. DOI: https://doi.org/10.7554/eLife.45881.007
Figure 2. Dynamic changes in RGC morphology and visual function in living SOHU animals. (A) Representative OCT images of mouse retina. Green circle indicates the OCT scan area surrounding ON head. GCC: ganglion cell complex, including RNFL, GCL and IPL layers, indicated by double end arrows. (B) Quantification of GCC thickness, represented as percentage of GCC thickness in the SO eyes, compared to the CL eyes. n = 10–20. (C) Visual acuity measured by OKR, represented as percentage of visual acuity in the SO eyes, compared to the CL eyes. n = 10–20. (D) Representative PERG traces for CL and SO eyes. (E) Quantification of PERG amplitude. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
amplitude ratio of the SO eyes to CL eyes decreased significantly (Figure 2D,E). However, that the lack of progression of PERG amplitude reduction suggests the SO itself may affect the light stimulation and PERG signal or the limitations of detection by PERG. Nevertheless, these results suggest that RGCs are very sensitive to IOP elevation, but resilient for a period of time before further degeneration. Taken together, these in vivo results show that SOHU eyes developed progressive structural and visual function deficits that closely resemble changes in glaucoma patients.

Glucomatous degeneration of RGC somata and axons in SOHU eyes
In vivo functional and imaging results indicate significant neurodegeneration in SOHU eyes, and histological analysis of post-mortem tissue samples supports these findings. We quantified surviving RGC somata in retinal wholemounts and surviving axons in ON semithin cross-sections at multiple time points after SO injection. Similar to the changes of GCC thickness measured by OCT in vivo, there was no statistical significance in surviving RGC counts in the peripheral retina between SOHU and control eyes at 1wpi, whereas there was significant and worsening RGC loss at 3, 5 and 8wpi, when only 43, 28, and 12% of peripheral RGCs survived (Figure 3A,B). This result confirmed significant progressive RGC death in response to IOP elevation in SOHU eyes. Significant RGC axon degeneration also occurred in SOHU ONs; only 57, 41% and 35% RGC axons survived at 3, 5, and 8wpi (Figure 3A,C). Therefore, IOP elevation in SOHU mouse eyes produces glaucomatous RGC and ON degeneration that starts as early as 3wpi and becomes progressing more severe at later time points that correlate with visual function deficits.

Although the SO used in these studies was sterile and safe for human use, we considered that toxicity might play a role in RGC death. Two experiments, however, provided evidence against this possibility: First, SO intravitreal injection did not cause significant IOP elevation, visual function deficits, or RGC/ON degeneration at 8wpi (Figure 4A–F). Second, the eyes with small SO droplets (<1.5 mm) and unstable IOP elevation (Figure 1D) showed no significant RGC death or axon degeneration at 8wpi (Figure 4G,H). Therefore, we conclude that the neurodegeneration phenotypes observed in SOHU eyes are glaucomatous responses to ocular hypertension.

SOHU is a reversible ocular hypertension model
One of the disadvantages of many other glaucoma models is that the initial eye injury is irreversible. However, we were able to flush out the SO from the anterior chamber with the aid of normal saline infiltration (Figure 5A, Video 5). This procedure lowered the IOP back to normal quickly and stably (Figure 5B), suggesting that SOHU is a reversible model that can be used to test whether lowering IOP affects degeneration of glaucomatous RGCs or the combination effect with neuroprotection.

Discussion
A reliable animal glaucoma model that closely mimics the disease in humans is a prerequisite for studies of pathogenetic mechanisms and for selecting efficient neuroprotective treatments for clinical use. In the present study, we developed a highly effective and reproducible method adopted from a clinical secondary glaucoma complication after retina surgery. Injection of SO to the mouse anterior chamber efficiently induces a series of reactions, including pupillary block, blockage of the aqueous humor outflow from anterior chamber, accumulation of aqueous humor in the posterior chamber, closure of the anterior chamber angle, and IOP elevation. These reactions occur without causing overt ocular structural damage or inflammatory responses while simulating acute glaucomatous changes that human patients develop over years by inducing progressive RGC and ON degeneration and visual functional deficits within weeks.
SO injection is limited to one eye in each mouse, with the other eye receiving an equivalent volume of normal saline. This serves as a convenient internal control for the surgical procedure and for studies of RGC morphology and function. It is reasonable to conclude that IOP is elevated in the SOHU eyes because of impeded inflow and accumulation of aqueous humor in the posterior
Figure 4. SO itself does not cause glaucomatous degeneration. (A) IOP measurements at different time points after intravitreal SO injection. n = 15. (B) Visual acuity measured by OKR, represented as percentage of visual acuity in the SO eyes, compared to the CL eyes. n = 13–15. (C) Quantification of P1-N2 amplitude of PERG, represented as percentage of P1-N2 amplitude in the SO eyes, compared to the CL eyes. n = 12–15. (D) Quantification of GCC thickness measured by OCT, represented as percentage of GCC thickness in the SO eyes, compared to the CL eyes. n = 11–13. (E) Upper panel, Figure 4 continued on next page
confocal images of portions of flat-mounted retinas showing surviving RBPMS-positive (red) RGCs at 8wpi after intravitreal SO injection and contralateral naive eye. Scale bar, 20 μm. Lower panel, light microscope images of semi-thin transverse sections of ON stained with PPD at 8wpi after intravitreal SO injection and contralateral naive eye. Scale bar, 10 μm. (F) Quantification of surviving RGCs (n = 10) and surviving axons in ON (n = 10) at 8wpi after intravitreal SO injection, represented as percentage of SO eyes compared to the CL eyes. Data are presented as means ± s.e.m, Student t-test. (G) Upper panel, confocal images of portion of flat-mounted retinas showing surviving RBPMS positive (red) RGCs at 8wpi after intracameral SO injection (small size of SO droplet ≤1.5 mm) and contralateral naive eye. Scale bar, 20 μm. Lower panel, light microscope images of semi-thin transverse sections of ON stained with PPD at 8wpi after intracameral SO injection and contralateral naive eye. Scale bar, 10 μm. (H) Quantification of surviving RGCs (n = 12) and surviving axons in ON (n = 13) at 8wpi, represented as percentage of SO eyes compared to the CL eyes. Data are presented as means ± s.e.m, Student t-test.

DOI: https://doi.org/10.7554/eLife.45881.010

segment of the eye, rather than by an aspect of the surgical procedure, such as the cornea wound or inflammation, which was rare. Although we never observed small emulsified SO droplets in any of

Figure 5. SOHU is reversible by SO removal. (A) Representative images of SOHU eyes before and after SO removal, and anterior chamber OCT images in living animals showing the relative size of SO droplet to pupil and the corresponding closure or opening of the anterior chamber angle before and after SO removal. (B) IOP measurements before and after SO removal at different time points. n = 16.

DOI: https://doi.org/10.7554/eLife.45881.011
the mouse eyes, we cannot exclude the possibility that at least in some cases oil occluded the TM. One previous glaucoma model elevated IOP in rats by injecting hyaluronic acid to impede aqueous outflow from TM (Mayordomo-Febrer et al., 2015; Benozzi et al., 2002; Moreno et al., 2005), indicating the possibility of TM damage due to repeated injection of a viscoelastic solution into anterior chamber. However, two of our observations provide evidence against this notion by indicating that TM function is normal in our model: 1. Pupillary dilation for an extended period of time eventually allows adequate aqueous clearance through TM and downregulation of IOP. 2. SO removal quickly returns IOP to normal, which indicates that the SO droplet is a prerequisite for IOP elevation. The relatively small variability in the duration and magnitude of IOP elevation in SOHU eyes after a single injection makes it a simple and reliable ocular hypertension model, which can be explained by the persistence of a SO droplet that is large relative to the size of the pupil.

Because of the unique feature of pupillary block associated with SOHU, the IOP is elevated in the posterior part of the eye, but not in the anterior chamber. We postulate that, after the pupil is sealed by SO, the large mouse lens, together with the iris and ciliary body, forms a rigid barrier that essentially disconnects the anterior and posterior chambers and thus shields the anterior chamber from the high pressure in the posterior chamber. This pathogenesis gives the model two advantageous characteristics: 1) The anterior segments of the experimental eyes are not substantially affected, leaving clear ocular elements that allow easy and reliable assessment of in vivo visual function and morphology; 2) The high IOP of the posterior chamber causes pronounced glaucomatous neurodegeneration within 5–8 weeks, which facilitates testing neuroprotectants by allowing any benefit to be detected in a short period of experimental time. One caveat, however, is that SO itself in anterior chamber may blur vision or affect the visual function assays because its optical characteristics differ from those of aqueous humor. These differences may cause early decreases in visual acuity and PERG amplitude at 1wpi, when OCT imaging, which does not depend on the transparency of anterior segment of the eye, shows no significant morphological degeneration. It is also possible that deficits in visual function precede morphological changes, or that there is no proportional relationship between RGC function and RGC morphology, since the visual acuity and PERG amplitude are not always correlated with RGC numbers. An assay of visual function that is unaffected by SO in the anterior chamber and that is more quantitatively related to RGC numbers is needed to resolve the discrepancy definitively.

The SOHU model is excellent for deciphering the key components of the degeneration cascade associated with ocular hypertension, but it is not suitable for TM function/deficit studies because it depends on pupillary block and spares TM. Because the IOP elevation is rapid and neurodegeneration severe within a few weeks, the SOHU model has features of acute secondary glaucoma in humans, but the extent to which it also mimics more chronic and milder primary glaucoma in patients needs further investigation. Human secondary angle-closure glaucoma is accompanied by RGC and significant photoreceptor loss (Panda and Jonas, 1992; Janssen et al., 1996; Nork et al., 2000), which may at least in part be due to ischemia caused by high IOP. Decreased blood flow through the choroidal circulation and ophthalmic artery has been reported in primary open angle glaucoma patients as well (Rojanapongpun et al., 1993; Michelson et al., 1995; Cellini et al., 1996; Yamazaki and Drance, 1997; Butt et al., 1997; Kaiser et al., 1997; Yin et al., 1997). A modified SOHU model that induces and maintains a moderate elevation of IOP through frequent pupil dilation may more closely reproduce the features of clinical primary open angle glaucoma.

In summary, this novel mouse acute ocular hypertension glaucoma model replicates secondary post-operative glaucoma. It is straightforward, does not require special equipment or repeat injections, and may be applicable to a range of animal species with only minor modifications.
reversible by removing SO from the anterior chamber and particularly useful for screening neuroprotective therapies in vivo. Therefore we report this simple, convenient, effective, reproducible, and reversible mouse model that generates stable, robust IOP elevation and significant neurodegeneration within weeks with the hopes that it will standardize assessment of the pathogenesis of ocular hypertension-induced glaucoma and facilitate selection of neuroprotectants for glaucoma.

### Materials and methods

#### Key resources table

| Reagent type (species) or resource | Designation          | Source or reference       | Identifiers | Additional information |
|-----------------------------------|-----------------------|---------------------------|-------------|------------------------|
| Strain, strain background (Mus musculus) | C57BL/6J              | Jackson Laboratories      | 000664      |                        |
| Antibody                         | anti-RBPMS (guinea pig polyclonal) | Custom-made by ProSci    |             | 1:4000                 |
| Antibody                         | Cy3 Goat anti-Guinea Pig IgG | Jackson ImmunoResearch    | 106-165-003 | 1:200                  |
| Chemical compound, drug          | Silicone oil          | Alcon Laboratories        | 1,000 mPa.s, Silikon |            |
| Software, algorithm              | Graphpad prism6       | GraphPad Software         |             |                        |
| Software, algorithm              | Volocity software     | Quorum Technologies       |             |                        |

#### Mice

C57BL/6J WT mice were purchased from Jackson Laboratories (Bar Harbor, Maine). For all surgical and treatment comparisons, control and treatment groups were prepared together in single cohorts, and the experiment repeated at least twice. All experimental procedures were performed in compliance with animal protocols approved by the IACUC at Stanford University School of Medicine.

#### Induction of IOP elevation by intracameral injection of SO

Male mice received SO injection at 9–10 weeks of age. Mice were anesthetized by an intraperitoneal injection of Avertin (0.3 mg/g) instead of ketamine/xylazine to avoid pupil dilation. The mice were then placed in a lateral position on a surgery platform. Prior to injection, one drop of 0.5% proparacaine hydrochloride (Akorn, Somerset, New Jersey) was applied to the cornea to reduce its sensitivity during the procedure. A 32G needle was tunneled through the layers of the cornea at the superotemporal side close to the limbus to reach the anterior chamber without injuring lens or iris. Following this entry, about 2 μl silicone oil (1,000 mPa.s, Silikon, Alcon Laboratories, Fort Worth, Texas) were injected slowly into the anterior chamber using a homemade sterile glass micropipette, until the oil droplet expanded to cover most areas of the iris. The micropipette was held in place for 30 s before withdrawing it slowly. After the injection, the upper eyelid was gently massaged to close the corneal incision to minimize SO leakage, and veterinary antibiotic ointment (BNP ophthalmic ointment, Vetropolyclin, Dechra, Overland Park, Kansas) was applied to the surface of the injected eye. The contralateral control eyes received 2 μl normal saline to the anterior chamber. During the whole procedure, artificial tears (Systane Ultra Lubricant Eye Drops, Alcon Laboratories, Fort Worth, Texas) were applied to keep the cornea moist. The rare mouse that showed corneal opacity associated with band-shaped degeneration or neovascularization was excluded from further analysis.

#### Removing SO from the anterior chamber

The oil droplet was removed from the anterior chamber at 3wpi. Mice were anesthetized by intraperitoneal injection of Avertin (0.3 mg/g) and placed in a lateral position on a surgery platform. Prior to injection, one drop of 0.5% proparacaine hydrochloride (Akorn, Somerset, New Jersey) was applied to the cornea to reduce its sensitivity during the procedure. Then two corneal tunnel
incisions were made using a 32G needle: one tunnel incision superior and one tunnel incision inferior to the center of the cornea, each at the edge of the oil droplet. A 33G needle attached to an elevated balanced salt solution plus (BSS Plus, Alcon Laboratories, Ft. Worth, Texas) drip (110 cm H₂O height, equal to 81 mmHg) was inserted through the superior corneal incision to flow BSS into anterior chamber to maintain its volume. At the same time, another 33G needle attached to a 1 mL syringe with the plunger removed, was inserted through the inferior tunnel incision to allow SO outflow. After removing the oil, a small air bubble was injected by a glass micropipette into anterior chamber to maintain the volume of anterior chamber and temporarily seal the corneal incision. Veterinary antibiotic ointment (BNP ophthalmic ointment) was applied to the surface of the eye.

IOP measurement
The IOP of both eyes was monitored once weekly until 8 weeks after SO injection using the TonoLab tonometer (Colonial Medical Supply, Espoo, Finland) according to product instructions. Briefly, in the morning, mice were anesthetized with a sustained flow of isoflurane (3% isoflurane at 2 L/minute mixed with oxygen) delivered to the nose by a special rodent nose cone (Xenotec, Inc, Rolla, Missouri), which left the eyes exposed for IOP measurement. The TonoLab tonometer takes five measurements, eliminates high and low readings and generates an average. We considered this machine-generated average as one reading. Three machine-generated readings were obtained from each eye every 5 min, and the mean was calculated to determine the IOP. During this procedure, artificial tears were applied to keep the cornea moist.

Immunohistochemistry of whole-mount retina and RGC counting
After transcardiac perfusion with 4% PFA in PBS, the eyes were dissected out, post-fixed with 4% PFA for 2 hr, at room temperature, and cryoprotected in 30% sucrose at 4°C overnight. Retinas were dissected out and washed extensively in PBS before blocking in staining buffer (10% normal goat serum and 2% Triton X-100 in PBS) for half an hour. RBPMS guinea pig antibody made at ProSci, California according to publications (Kwong et al., 2010; Rodriguez et al., 2014) and used at 1:4000, and rat HA (clone 3F10, 1:200, Roche) were diluted in the same staining buffer. Floating retinas were incubated with primary antibodies overnight at 4°C and washed 3 times for 30 min each with PBS. Secondary antibodies (Cy2 or Cy3) were then applied (1:200–400; Jackson ImmunoResearch, West Grove, Pennsylvania) and incubated for 1 hr at room temperature. Retinas were again washed 3 times for 30 min each with PBS before a cover slip was attached with Fluoromount-G (SouthernBiotech, Birmingham, Alabama). For peripheral RGC counting, whole-mount retinas were immunostained with the RBPMS antibody, 6–9 fields sampled from peripheral regions of each retina using 40x lens with a Zeiss M2 epifluorescence microscope, and RBPMS +RGCs counted by Volocity software (Quorum Technologies). The percentage of RGC survival was calculated as the ratio of surviving RGC numbers in injured eyes compared to contralateral uninjured eyes. The investigators who counted the cells were masked to the treatment of the samples.

ON semi-thin sections and quantification of surviving axons
After mice were perfused through the heart with ice cold 4% paraformaldehyde (PFA) in PBS, the ON was exposed by removing the brain and post-fixed in situ using 2% glutaraldehyde/2% PFA in 0.1M PB for 4 hr. Samples were then washed with 0.1M PB three times, 10 min each wash. The ONs were then carefully dissected out and rinsed with 0.1M PB three times, 10 min each wash. They were then incubated in 1% osmium tetroxide in 0.1M PB for 1 hr at room temperature followed by washing with 0.1M PB for 10 min and water for 5 min. ONs were next dehydrated through a series of graded ethanol (50% to 100%), rinsed twice with propylene oxide (P.O.), 3 min each rinse, and transferred to medium containing 50% EMbed 812/50% P.O. overnight. The next day, the medium was changed to a 2:1 ratio of EMbed 812/P.O. ONs remained in this mixture overnight, then were transferred to 100% EMbed 812 on a rotator for another 6 hr, embedded in a mold filled with 100% EMbed 812 and incubated at 60°C overnight. Semi-thin sections (1 μm) were cut on an ultramicrotome (EM UC7, Leica, Wetzlar, Germany) and collected 2 mm distal to the eye. The semi-thin sections were attached to glass slides and stained with 1% para-phenylenediamine (PPD) in methanol: isopropanol (1:1) for 35 min. After rinsing three times with methanol: isopropanol (1:1), coverslips were applied with Permount Mounting Medium (Electron Microscopy Sciences, Hatfield,
Pennsylvania). PPD stains all myelin sheaths, but darkly stains the axoplasm only of degenerating axons, which allows us to differentiate surviving axons from degenerating axons (Smith et al., 2002). Four sections of each ON were imaged through a 100x lens of a Zeiss M2 epifluorescence microscope to cover the entire area of the ON without overlap. Two areas of 21.4 μm X 29.1 μm were cropped from the center of each image, and the surviving axons within the designated areas were counted manually. After counting all the images taken from a single nerve, the mean of the surviving axon number was calculated for each ON. The mean of the surviving axon number in the injured ON was compared to that in the contralateral control ON to yield a percentage of axon survival value. The investigators who counted the axons were masked to the treatment of the samples.

**Intravitreal injection**

These procedures have been described previously (Hu et al., 2012; Yang et al., 2014). Briefly, mice were anesthetized by xylazine and ketamine based on their body weight (0.01 mg xylazine/g + 0.08 mg ketamine/g). For intravitreal dye injection, Dil solution (ThermoFisher Scientific, V22885) was injected into posterior chamber through the point directly behind the limbus (beneath the iris) to demonstrate aqueous humor migration.

**Pattern electroretinogram (PERG) recording**

Mice were anesthetized by xylazine and ketamine based on their body weight (0.01 mg xylazine/g + 0.08 mg ketamine/g). PERG recording of both eyes was performed at the same time with the Miami PERG system (Intelligent Hearing Systems, Miami, FL) according to published protocol (Chou et al., 2014). Briefly, mice were placed on a feedback-controlled heating pad (TCAT-2LV, Physitemp Instruments Inc, Clifton, New Jersey) to maintain animal core temperature at 37°C. A small lubricant eye drop (Systane Ultra Lubricant Eye Drops, Alcon Laboratories, Ft. Worth, Texas) was applied before recording to prevent corneal dryness. The reference electrode was placed subcutaneously on the back of the head between the two ears and the ground electrode was placed at the root of the tail. The active steel needle electrode was placed subcutaneously on the snout for the simultaneous acquisition of left and right eye responses. Two 14 cm x 14 cm LED-based stimulators were placed in front so that the center of each screen was 10 cm from each eye. The pattern remained at a contrast of 85% and a luminance of 800 cd/m², and consisted of four cycles of black-gray elements, with a spatial frequency of 0.052 c/d. Upon stimulation, the independent PERG signals were recorded from the snout and simultaneously by asynchronous binocular acquisition. With each trace recording up to 1020 ms, two consecutive recordings of 200 traces were averaged to achieve one readout. The first positive peak in the waveform was designated as P1 (typically around 100 ms) and the second negative peak as N2 (typically around 205 ms). The amplitude was measured from P1 to N2. The mean of the P1-N2 amplitude in the injured eye was compared to that in the contralateral control eye to yield a percentage of amplitude change. The investigators who measured the amplitudes were masked to the treatment of the samples.

**Spectral-domain optical coherence tomography (SD-OCT) imaging**

After the mice were anesthetized, pupils were dilated by applying 1% tropicamide sterile ophthalmic solution (Akorn, Somerset, New Jersey), and a customized +10D contact lens (3.0 mm diameter, 1.6 mm BC, PMMA clear, Advanced Vision Technologies) applied to the dilated pupil. The retina fundus images were captured with the Heidelberg Spectralis SLO/OCT system (Heidelberg Engineering, Germany) equipped with an 870 nm infrared wavelength light source and a 30° lens (Heidelberg Engineering). The OCT scanner has 7 μm optical axial resolution, 3.5 μm digital resolution, and 1.8 mm scan depth at 40 kHz scan rate. The mouse retina was scanned with the ring scan mode centered by the optic nerve head at 100 frames average under high-resolution mode (each B-scan consisted of 1536 A scans). The GCC includes retinal nerve fiber layer (RNFL), ganglion cell layer (GCL) and inner plexiform layer (IPL). The average thickness of GCC around the optic nerve head was measured manually with the aid of Heidelberg software. The mean of the GCC thickness in the injured retina was compared to that in the contralateral control retina to yield a percentage of GCC thickness value. The investigators who measured the thickness of GCC were masked to the treatment of the samples.
OKR measurement

To measure the spatial vision using the opto-kinetic response (OKR), mice were placed unrestrained on a platform in the center of four 17-inch LCD computer monitors (Dell, Phoenix, AZ), with a video camera above the platform to capture the movement of the mouse. A rotating cylinder with vertical sine wave grating was computed and projected to the four monitors by OptoMotry software (CerebralMechanics Inc, Lethbridge, Alberta, Canada). The sine wave grating, consisting of black (mean luminance 0.22 cd/m²) and white (mean luminance 152.13 cd/m²) at 100% contrast and 12 degree/second, provides a virtual-reality environment to measure the spatial acuity of left eye when rotates clockwise and right eye when it rotates counterclockwise. Initially, the monitors were covered with gray so that the mouse calmed down and stopped moving, then the gray was switched to a low spatial frequency (0.1 cycle/degree) for five seconds, during which the mouse was assessed for whether the head turned to track the grating. The short time frame of assessment ensures that the mice did not adapt to the stimulus, which would lead to false readouts. When the mouse was determined to be capable of tracking the grating, the spatial frequency was increased repeatedly until the maximum frequency was identified and recorded. At each time point, the maximum frequency of the experimental eye was compared to that of the contralateral eye. The mice were tested in the morning and the investigator who judged the OKR was masked to the treatment of mice.

Statistical analyses

GraphPad Prism six was used to generate graphs and for statistical analyses. Data are presented as means ± s.e.m. Student’s t-test was used for two groups comparison and One-way ANOVA with post hoc test was used for multiple comparisons.

Acknowledgements

We thank Drs. Zhigang He and Alan Tessler for critically reading the manuscript. We also appreciate the help from Gang Jiang and Niannian Liu in making schematic diagrams in Figure 1A. YH is supported by NIH grants EY024932, EY023295 and EY028106 and grants from BrightFocus Foundation, Glaucoma Research Foundation, National Multiple Sclerosis Society and William and Mary Greve Special Scholar Award from Research to Prevent Blindness. Portions of this work were supported by NIH grants EY026766 and EY027261 to JLG and NIH grants EY-25295, K08-EY022058, VA CX001298, Ziegler Foundation for the Blind to YS, who is a Stanford Child Health Research Institute Laurie Kraus Lacob Faculty Scholar. HCW is supported by NIH T32 Postdoctoral Fellowship (NEI T32 EY027816). We are grateful for an unrestricted grant from Research to Prevent Blindness and NEI P30-026877 to the Department of Ophthalmology. The authors have declared that no conflict of interest exists.

Additional information

| Funder                      | Grant reference number     | Author               |
|-----------------------------|-----------------------------|----------------------|
| National Eye Institute      | NEI T32 EY027816            | Hannah C Webber      |
| National Eye Institute      | EY-25295                   | Yang Sun             |
| National Eye Institute      | K08-EY022058               | Yang Sun             |
| U.S. Department of Veterans Affairs | VA CX001298                | Yang Sun             |
| E. Matilda Ziegler Foundation for the Blind | EY026766                  | Yang Sun             |
| National Eye Institute      | EY027261                   | Jeffrey L Goldberg   |
| National Eye Institute      | EY024932                   | Yang Hu              |
| National Eye Institute      | EY023295                   | Yang Hu              |
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions
Jie Zhang, Liang Li, Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—review and editing; Haoliang Huang, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—review and editing; Fang Fang, Data curation, Validation, Methodology; Hannah C Webber, Investigation, Visualization, Writing—review and editing; Pei Zhuang, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—review and editing; Liang Liu, Validation, Investigation, Methodology; Roopa Dalal, Investigation, Methodology; Peter H Tang, Vinit B Mahajan, Shaohua Li, Mingchang Zhang, Conceptualization, Writing—review and editing; Yang Sun, Investigation, Writing—review and editing; Jeffrey L Goldberg, Conceptualization, Investigation, Writing—review and editing; Yang Hu, Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing—original draft, Project administration, Writing—review and editing

Author ORCIDs
Jeffrey L Goldberg http://orcid.org/0000-0002-1390-7360
Yang Hu https://orcid.org/0000-0002-7980-1649

Ethics
Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#32093) of the Stanford University.

Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.45881.014
Author response https://doi.org/10.7554/eLife.45881.015

Additional files

Data availability
All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for all the figures.

References
Aihara M, Lindsey JD, Weinreb RN. 2003. Experimental mouse ocular hypertension: establishment of the model. Investigative Ophthalmology & Visual Science 44:4314–4320. DOI: https://doi.org/10.1167/iovs.03-0137
Aktas O, Albrecht P, Hartung HP. 2016. Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives. Current Opinion in Neurology 29:199–204. DOI: https://doi.org/10.1097/WCO.0000000000000327, PMID: 27035900
Balcer LJ, Miller DH, Reingold SC, Cohen JA. 2015. Vision and vision-related outcome measures in multiple sclerosis. Brain 138:11–27. DOI: https://doi.org/10.1093/brain/awu335, PMID: 25433914

Benozzi J, Nahum LP, Campanelli JL, Rosenste RE. 2002. Effect of hyaluronic acid on intraocular pressure in rats. Investigative Ophthalmology & Visual Science 43:2196–2200. PMID: 12091416

Burgoyne CF. 2011. A biomechanical paradigm for axonal insult within the optic nerve head in aging and glaucoma. Experimental Eye Research 93:120–132. DOI: https://doi.org/10.1016/j.exer.2010.09.005, PMID: 20849846

Burroughs SL, Kaja S, Koulen P. 2011. Quantification of deficits in spatial visual function of mouse models for glaucoma. Investigative Ophthalmology & Visual Science 52:3654–3659. DOI: https://doi.org/10.1167/iovs.10-7106

Butt Z, O’Brien C, McKillop G, Aspinall P, Allan P. 1997. Color doppler imaging in untreated high- and normal-pressure open-angle glaucoma. Investigative Ophthalmology & Visual Science 38:690–696. PMID: 9071223

Calkins DJ. 2012. Critical pathogenic events underlying progression of neurodegeneration in glaucoma. Progress in Retinal and Eye Research 31:702–719. DOI: https://doi.org/10.1016/j.preteyeres.2012.07.001, PMID: 22871543

Cellini M, Possati GL, Caramazza N, Caramazza R. 1996. Colour doppler analysis of the choroidal circulation in chronic open-angle glaucoma. Ophthalmologica 210:200–202. DOI: https://doi.org/10.1159/000310708, PMID: 8841063

Chen H, Wei X, Cho K-S, Chen G, Sappington R, Calkins DJ, Chen DF. 2011. Optic neuropathy due to Micro bead-Induced elevated intracocular pressure in the mouse. Investigative Ophthalmology & Visual Science 52:28–44. DOI: https://doi.org/10.1167/iovs.09-5115

Chen S, Zhang X. 2015. The rodent model of glaucoma and its implications. Asia-Pacific Journal of Ophthalmology 4:236–241. DOI: https://doi.org/10.1097/PAO.0000000000000122, PMID: 26147015

Chou T-H, Bohorquez J, Toft-Nielsen J, Ozdamar O, Porciatti V. 2014. Robust mouse pattern electroretinograms derived simultaneously from each eye using a common snout electrode. Investigative Ophthalmology & Visual Science 55:2469–2475. DOI: https://doi.org/10.1167/iovs.14-13943

Cone FE, Gelman SE, Son JL, Pease ME, Quigley HA. 2010. Differential susceptibility to experimental glaucoma among 3 mouse strains using bead and viscoelastic injection. Experimental Eye Research 91:415–424. DOI: https://doi.org/10.1016/j.exer.2010.06.018, PMID: 20599961

Costello F, Coupland S, Hodge W, Loretro GR, Koroluk J, Pan YI, Freedman MS, Zackon DH, Kardon RH. 2006. Quantifying axonal loss after optic neuritis with optical coherence tomography. Annals of Neurology 59:963–969. DOI: https://doi.org/10.1002/ana.20851

Douglas RM, Alam NM, Silver BD, McGill TJ, Tschetter WW, Prusky GT. 2005. Independent visual threshold measurements in the two eyes of freely moving rats and mice using a virtual-reality optokinetic system. Visual Neuroscience 22:677–684. DOI: https://doi.org/10.1017/S0952523805225166, PMID: 16322278

Douglas RM, Neve A, Quittenbaum JP, Alam NM, Prusky GT. 2006. Perception of visual motion coherence by rats and mice. Vision Research 46:2842–2847. DOI: https://doi.org/10.1016/j.visres.2006.02.025, PMID: 16447739

Early Manifest Glaucoma Trial Group, Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. 2002. Reduction of intracocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Archives of Ophthalmology 120:1268–1279. DOI: https://doi.org/10.1001/archopht.120.10.1268, PMID: 12365904

Grozdanic SD, Betts DM, Sakaguchi DS, Albabaugh RA, Kwon YH, Kardon RH. 2003. Laser-Induced mouse model of chronic ocular hypertension. Investigative Ophthalmology & Visual Science 44:4337–4346. DOI: https://doi.org/10.1167/iovs.03-0015

Howell GR, Libby RT, Jakobs TC, Smith RS, Phalan FC, Barter JW, Barbay JM, Marchant JK, Mahesh N, Porciatti V, Whitmore AV, Masland RH, John SW. 2007. Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma. The Journal of Cell Biology 179:1523–1537. DOI: https://doi.org/10.1083/jcb.200706181, PMID: 18158332

Hu Y, Park KK, Yang L, Wei X, Yang Q, Cho KS, Thielen P, Lee AH, Cartoni R, Glimcher LH, Chen DF, He Z. 2012. Differential effects of unfolded protein response pathways on axon injury-induced death of retinal ganglion cells. Neuron 73:445–452. DOI: https://doi.org/10.1016/j.neuron.2011.11.026, PMID: 22325198

Ichihjupiani P, Jindal A, Jay Katz L. 2009. Silicon oil induced glaucoma: a review. Graefe’s Archive for Clinical and Experimental Ophthalmology 247:1585–1593. DOI: https://doi.org/10.1007/s00417-009-1155-x, PMID: 19685070

Ito YA, Belforte N, Cueva Vargas JL, Di Polo A. 2016. A magnetic microbead occlusion model to induce ocular Hypertension-Dependent glaucoma in mice. Journal of Visualized Experiments 109:e53731. DOI: https:// doi.org/10.3791/53731

Janssen P, Naskar R, Moore S, Thanos S, Thiel HJ. 1996. Evidence for glaucoma-induced horizontal cell alterations in the human retina. German Journal of Ophthalmology 5:378–385. PMID: 9479522

Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. 2017. Glaucoma. The Lancet 390:2183–2193. DOI: https://doi.org/10.1016/S0140-6736(17)31469-1

Kaiser HJ, Schoetzau A, Stumppf G, Flammer J. 1997. Blood-flow velocities of the extraocular vessels in patients with high-tension and low-tension primary open-angle glaucoma. American Journal of Ophthalmology 123:320–327. DOI: https://doi.org/10.1016/S0002-9394(14)70127-8, PMID: 9063241

Kornmann HL, Gedde SJ. 2016. Glaucoma management after vitreoretinal surgeries. Current Opinion in Ophthalmology 27:125–131. DOI: https://doi.org/10.1097/ICU.0000000000000238, PMID: 26595848
Kwong JMK, Caprioli J, Piri N. 2010. RNA binding protein with multiple splicing: a new marker for retinal ganglion cells. *Investigative Ophthalmology & Visual Science* **51**:1052–1058. DOI: https://doi.org/10.1167/iovs.09-4098

Libby RT, Li Y, Savinova OV, Barter J, Smith RS, Nickells RW, John SWM. 2005. Susceptibility to neurodegeneration in a glaucoma is modified by bax gene dosage. *PLOS Genetics* **1**:4–26. DOI: https://doi.org/10.1371/journal.pgen.0010004

Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills RP, CIGTS Study Group. 2001. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. *Ophthalmology* **108**:1943–1953. DOI: https://doi.org/10.1016/S0161-6420(01)00873-9, PMID: 11713061

Mayordomo-Febrer A, López-Murcia M, Morales-Tatay JM, Monleón-Salvado D, Pinozo-Durán MD. 2015. Metabolomics of the aqueous humor in the rat glaucoma model induced by a series of intracameral sodium hyaluronate injection. *Experimental Eye Research* **131**:84–92. DOI: https://doi.org/10.1016/j.exer.2014.11.012, PMID: 25470946

McKinnon SJ, Schlamp CL, Nickells RW. 2009. Mouse models of retinal ganglion cell death and glaucoma. *Experimental Eye Research* **88**:816–824. DOI: https://doi.org/10.1016/j.exer.2008.12.002, PMID: 19105954

Michelson G, Groh MJ, Groh ME, Gründler A. 1995. Advanced primary open-angle glaucoma is associated with decreased ophthalmic artery blood-flow velocity. *German Journal of Ophthalmology* **4**:21–24. PMID: 7728106

Moreno MC, Marcos HJ, Oscar Croxatto J, Sande PH, Campanelli J, Jaliffa CO, Benozzi J, Rosenstein RE. 2005. A new experimental model of glaucoma in rats through intracameral injections of hyaluronic acid. *Experimental Eye Research* **81**:71–80. DOI: https://doi.org/10.1016/j.exer.2005.01.008, PMID: 15978257

Morrison JC, Johnson E, Cepurna WO. 2008. Rat models for glaucoma research. *Progress in Brain Research* **173**:285–301. DOI: https://doi.org/10.1016/S0079-6123(08)01121-7, PMID: 18929117

Nakano N, Ikeda HO, Hangai M, Muraoka Y, Toda Y, Kakizuka A, Yoshimura N. 2011. Longitudinal and simultaneous imaging of retinal ganglion cells and inner retinal layers in a mouse model of glaucoma induced by N-Methyl- d -Aspartate . *Investigative Ophthalmology & Visual Science* **52**:8754–8762. DOI: https://doi.org/10.1167/iovs.10-6654

Nickells RW, Howell GR, Soto I, John SW. 2012. Under pressure: cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy. *Annual Review of Neuroscience* **35**:153–179. DOI: https://doi.org/10.1146/annurev.neuro.051508.135728, PMID: 22524788

Nork TM, Ver Hoeve JN, Poulsen GL, Nickells RW, Davis MD, Weber AJ, Vaegan , Sarks SH, Lemley HL, Millecchia LL. 2000. Swelling and loss of photoreceptors in chronic human and experimental glaucomas. *Archives of Ophthalmology* **118**:235–245. DOI: https://doi.org/10.1001/archophthalm.118.2.235, PMID: 10676789

Panda S, Jonas JB. 1992. Decreased photoreceptor count in human eyes with secondary angle-closure glaucoma. *Investigative Ophthalmology & Visual Science** **33**:2532–2536. PMID: 1634350

Pang IH, Clark AF. 2007. Rodent models for glaucoma retinopathy and optic neuropathy. *Journal of Glaucoma* **16**:483–505. DOI: https://doi.org/10.1097/JIG.0b013e181405d4f4, PMID: 17700292

Porciatti V. 2015. Electrophysiological assessment of retinal ganglion cell function. *Experimental Eye Research* **141**:164–170. DOI: https://doi.org/10.1016/j.exer.2015.05.008, PMID: 25998495

Prusky GT, Alam NM, Beekman S, Douglas RM. 2004. Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. *Investigative Ophthalmology & Visual Science* **45**:4611–4616. DOI: https://doi.org/10.1167/iovs.04-0541

Quigley HA. 1993. Open-angle glaucoma. *New England Journal of Medicine* **328**:1097–1106. DOI: https://doi.org/10.1056/NEJM199904153281507, PMID: 8455668

Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. 1995. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. *Investigative Ophthalmology & Visual Science** **36**:774–786. PMID: 7706025

Rodriguez AR, de Sevilla Müller LP, Brecha NC. 2014. The RNA binding protein RBPM5 is a selective marker of ganglion cells in the mammalian retina. *Journal of Comparative Neurology* **522**:1411–1443. DOI: https://doi.org/10.1002/cne.23521, PMID: 24318667

Rojanapongpun P, Drance SM, Morrison BJ. 1993. Ophthalmic artery flow velocity in Glaucomatous and normal subjects. *British Journal of Ophthalmology* **77**:25–29. DOI: https://doi.org/10.1136/bjo.77.1.25, PMID: 8435394

Samsel PA, Kisiwai L, Erichsen JT, Cross SD, Morgan JE. 2011. A novel method for the induction of experimental glaucoma using magnetic microspheres. *Investigative Ophthalmology & Visual Science* **52**:1671–1675. DOI: https://doi.org/10.1167/iovs.09-3921

Sappington RM, Carlson BJ, Crish SD, Calkins DJ. 2010. The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice. *Investigative Ophthalmology & Visual Science* **51**:207–216. DOI: https://doi.org/10.1167/iovs.09-3947

Singh K, Shrivastava A. 2009. Intraocular pressure fluctuations: how much do they matter? *Current Opinion in Ophthalmology* **20**:84–87. DOI: https://doi.org/10.1097/ICO.0b013e3282324e6c4, PMID: 19248311

Smith RS, John SWM, Nisssha PM, Sundberg JP. 2002. Systematic Evaluation of the Mouse Eye: Anatomy, Pathology, and Biomethods. Boca Raton: CRC Press.

Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. 2014. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology* **121**:2081–2090. DOI: https://doi.org/10.1016/j.ophtha.2014.05.013, PMID: 24974815
The AGIS Investigators. 2000. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. *American Journal of Ophthalmology* **130**:429–440. DOI: https://doi.org/10.1016/S0002-9394(00)00538-9, PMID: 11024415

Varma R, Peeples P, Walt JG, Bramley TJ. 2008. Disease progression and the need for neuroprotection in glaucoma management. *The American Journal of Managed Care* **14**:S15–S19. PMID: 18284311

Varma R, Lee PP, Goldberg I, Kotak S. 2011. An assessment of the health and economic burdens of glaucoma. *American Journal of Ophthalmology* **152**:S15–S22. DOI: https://doi.org/10.1016/j.ajo.2011.06.004, PMID: 21961848

Weinreb RN, Khaw PT. 2004. Primary open-angle glaucoma. *The Lancet* **363**:1711–1720. DOI: https://doi.org/10.1016/S0140-6736(04)16257-0

Yamazaki Y, Drance SM. 1997. The relationship between progression of visual field defects and retrobulbar circulation in patients with glaucoma. *American Journal of Ophthalmology* **124**:287–295. DOI: https://doi.org/10.1016/S0002-9394(14)70820-7, PMID: 9439354

Yang L, Miao L, Huang H, Teng X, Li S, Nuriddinov J, Selzer ME, Hu Y. 2014. The mTORC1 effectors S6K1 and 4E-BP play different roles in CNS axon regeneration. *Nature Communications* **5**:5416. DOI: https://doi.org/10.1038/ncomms6416, PMID: 25382660

Yang L, Li S, Miao L, Huang H, Liang F, Teng X, Xu L, Wang Q, Xiao W, Ridder WH, Ferguson TA, Chen DF, Kaufman RJ, Hu Y. 2016. Rescue of glaucomatous neurodegeneration by differentially modulating neuronal endoplasmic reticulum stress molecules. *Journal of Neuroscience* **36**:5891–5903. DOI: https://doi.org/10.1523/JNEUROSCI.3709-15.2016, PMID: 27225776

Yin ZQ, Vaegan, Millar TJ, Beaumont P, Sarks S. 1997. Widespread choroidal insufficiency in primary open-angle glaucoma. *Journal of Glaucoma* **6**:23–32. DOI: https://doi.org/10.1097/00061198-199702000-00006, PMID: 9075077

Yun H, Lathrop KL, Yang E, Sun M, Kagemann L, Fu V, Stolz DB, Schuman JS, Du Y. 2014. A laser-induced mouse model with long-term intraocular pressure elevation. *PLOS ONE* **9**:e107446. DOI: https://doi.org/10.1371/journal.pone.0107446, PMID: 25216052